Chemo- and Enantioselective Rh-Catalyzed Hydrogenation of 3-Methylene-1,2-diazetidines: Application to Vicinal Diamine Synthesis

Greg P. Iacobini,^a David W. Porter,^b and Michael Shipman^{*a}

^a Department of Chemistry, University of Warwick, Gibbet Hill Road, Coventry, CV4 7AL, UK. Fax: +44 2476 524112; Tel: +44 2476 523186; E-mail: <u>m.shipman@warwick.ac.uk</u>

^b Novartis Institutes for BioMedical Research, Wimblehurst Road, Horsham Research Centre, West Sussex, RH12 5AB, UK.

Supplementary Information

| Hydrogenation procedures and characterisation data for 5a-c | 1-4 |
|--|------|
| LiDBB reductive cleavage of (S)-5a to (S)-19 | 5 |
| Synthesis and characterisation of (\pm) -19 and (R) -19 from commercial diaminopropane | 6 |
| ¹ H NMR of 19 in presence of (<i>S</i>)-Pirkle's reagent | 7-8 |
| ¹ H and ¹³ C NMR spectra of 5a-c , (<i>S</i>)- 19 | 9-16 |

General Hydrogenation Method. To a test tube containing a solution of the 3-methylene-1,2diazetidine **4** (1 molar equiv.) in EtOAc was added $[Rh(NBD)_2].BF_4$ (0.01 molar equiv.) followed by the ferrocene-based ligand (0.014 molar equiv). The test tube was placed within a high pressure Parr hydrogenator, purged with hydrogen three times and then charged with hydrogen to 50 bar. The reaction was stirred at the specified temperature for the required amount of time, then allowed to cool and concentrated *in vacuo*. Purification on silica gel (EtOAc in hexane) afforded the following compounds.

(R)-Diethyl 3-methyl-1,2-diazetidine-1,2-dicarboxylate (5a).



(*R*)-**5a** was synthesized according to the general procedure using **4a** (62 mg, 0.29 mmol), [Rh(NBD)₂].BF₄ (1 mg, 2.9 µmol), (*R*)-1-[(*S*_P)-2-(diphenylphosphino)ferrocenyl]ethyldicyclohexylphosphine (**6**) (2.5 mg, 4.1 µmol) and ethyl acetate (2 mL). Purification on silica gel (15 % ethyl acetate in hexane) afforded diethyl 1-(propyl)hydrazine-1,2-dicarboxylate (6 mg, 9%) as a colourless oil. IR (film) 3295 (N-H), 2983 (C-H), 1694 (C=O) cm⁻¹; ¹H NMR (400 MHz, CDCl₃) 6.31-6.64 (1H, m, H-2), 4.14-4.22 (4H, m, CO₂CH₂CH₃), 3.46 (2H, m, NCH₂CH₂CH₃), 1.59 (2H, sextuplet, *J* = 7.3 Hz, NCH₂CH₂CH₃), 1.24-1.28 (6H, m, CO₂CH₂CH₃), 0.90 (3H, t, *J* = 7.3 Hz, NCH₂CH₂CH₃); ¹³C NMR (100 MHz, CDCl₃) 156.3 (2C, CO₂CH₂CH₃), 62.4 (1C, CO₂CH₂CH₃), 62.0 (1C, CO₂CH₂CH₃), 20.7 (1C, NCH₂CH₂CH₃), 14.6 (1C, CO₂CH₂CH₃), 14.5 (1C, CO₂CH₂CH₃), 11.1 (1C, NCH₂CH₂CH₃); MS (ES⁺) *m/z* = 241 [M+Na]⁺, HRMS (ES⁺) *m/z* calculated for C₉H₁₈N₂O₄Na [M+Na]⁺: 241.1159; found: 241.1160. Further elucidation afforded **5a** (56 mg, 89%, 44% ee) as a colourless oil. [α]³⁰_D = 0.0 (*c* 1.50, EtOAc); IR (film) 2977 (CH₃), 1702 (C=O), 1273 (C-O) cm⁻¹; ¹H NMR (400 MHz, CDCl₃) 4.39-4.47 (1H, m, H-3), 4.32 (1H, t, *J* = 8.0 Hz, H-4), 4.15-4.27 (4H, m, CO₂CH₂CH₃), 3.74 (1H, dd, *J* = 6.2, 8.0 Hz, H-4), 1.48 (3H, d, J = 6.3 Hz, CHC<u>H₃</u>), 1.28 (6H, t, J = 7.2 Hz, CO₂CH₂C<u>H₃</u>); ¹³C NMR (100 MHz, CDCl₃) 161.1 (1C, <u>CO₂CH₂CH₃</u>), 160.9 (1C, <u>CO₂CH₂CH₃), 62.6 (1C, CO₂<u>C</u>H₂CH₃), 62.4 (1C, CO₂<u>C</u>H₂CH₃), 58.1 (1C, C-3), 56.1 (1C, C-4), 20.7 (1C, CH<u>C</u>H₃), 14.4 (2C, CO₂CH₂<u>C</u>H₃); MS (ES⁺) m/z = 239 [M+Na]⁺, HRMS (ES⁺) m/z calculated for C₉H₁₆N₂O₄Na [M+Na]⁺: 239.1002; found: 239.1004. Enantiopurity by HPLC analysis on a Chiralcel AD column (1.0 mL min⁻¹, 3% IPA in hexanes): $t_R 22.67$ (*major*) and 24.85 (*minor*) min.</u>

EtO₂C, CO₂Et (*S*)-Diethyl 3-methyl-1,2-diazetidine-1,2-dicarboxylate (5a). (*S*)-5a was synthesized according to the general procedure using 4a (250 mg, 1.17 mmol), [Rh(NBD)₂].BF₄ (5 mg, 17 µmol), (S_P , S'_P)-1,1'-Bis [bis(4-methoxy-3,5-dimethylphenyl) phosphino]-2,2'-bis [(*R*)-α-(dimethylamino)benzyl]ferrocene 18 (17 mg, 24 µmol) and EtOAc (2 mL). Purification on silica gel (15 % EtOAc in hexane) afforded 280 (244 mg, 98%, 89% ee) as a colourless oil. Spectroscopic data as previously described. Enantiopurity by HPLC analysis on a Chiralcel AD column (1.0 mL min⁻¹, 3% IPA in hexanes): t_R 22.67 (*minor*) and 24.85 (*major*) min.

EtO₂C, CO₂Et Diethyl 3-benzyl-1,2-diazetidine-1,2-dicarboxylate (5b). 5b was synthesised according to the general procedure using 4b (50 mg, 0.17 mmol), [Rh(NBD)₂]BF₄ (1 mg, 1.7 µmol), (*R*)-1-[(*S*_p)-2-(diphenyl-phosphino)ferrocenyl]ethyldicyclohexylphosphine (2 mg, 2.5 µmol), and EtOAc (2 mL). Purification of silica gel (20% EtOAc in hexane) afforded 282 (27 mg, 54% 33% ee) as a colourless oil. $[\alpha]^{30}_{D} = +36.0$ (*c*. 3.50, EtOAc); IR (film) 2984 (CH₃), 1705 (C=O), 1270 (C-O), 702 (Ar-H) cm⁻¹; ¹H NMR (400 MHz, CDCl₃) 7.18-7.30 (5H, m, ArH), 4.52-4.59 (1H, m, H-3), 4.06-4.26 (5H, m, H-4, CO₂CH₂CH₃), 3.82 (1H, dd, *J* = 6.0, 8.4 Hz, H-4), 3.11 (1H, dd, *J* = 5.0, 14.0 Hz, -CH<u>H</u>Ph), 3.04 (1H, dd, J = 7.7, 14.0 Hz, -C<u>H</u>HPh), 1.25 (3H, t, J = 7.1 Hz, CO₂CH₂C<u>H₃</u>), 1.22 (3H, t, J = 7.1 Hz, CO₂CH₂C<u>H₃</u>); ¹³C NMR (100 MHz, CDCl₃) 160.8 (2C, CO₂CH₂CH₃), 135.4 (1C, ArC), 129.5 (2C, ArCH), 128.4 (2C, ArCH), 126.4 (1C, ArCH), 62.5 (2C, CO₂CH₂CH₃), 62.1 (1C, C-3), 53.8 (1C, C-4), 40.2 (1C, -CH₂Ph), 14.4 (2C, CO₂CH₂CH₃); MS (ES⁺) m/z = 315 [M+Na]⁺, HRMS (ES⁺) m/z calculated for C₁₅H₂₀N₂O₄Na [M+Na]⁺: 315.1315; found: 315.1311. Enantiopurity by HPLC analysis on a Chiralcel AD column (1.0 mL min⁻¹, 5% IPA in hexanes): t_R 18.22 (*minor*) and 21.32 (*major*) min.

^{BuO₂C, CO₂Bu **Di***tert*-**butyl 3-methyl-1,2-diazetidine-1,2-dicarboxylate** (5c). 5c was synthesised according to the general procedure using 4c (50 mg, 0.19 mmol), [Rh(NBD)₂]BF₄ (1 mg, 1.9 µmol), (*R*)-1-[(*S*_P)-2-(diphenylphosphino)ferrocenyl]ethyldicyclohexylphosphine (2 mg, 2.7 µmol) and EtOAc (2 ml). Purification on silica gel (12.5% EtOAc in hexane) afforded 5c (38 mg, 76%, 60% ee) as a colourless oil. $[\alpha]^{30}_{D} = +24.5$ (*c* 1.25, EtOAc); IR (neat) 2979 (CH₃), 1700 (C=O), 1158 (C-O) cm⁻¹; ¹H NMR (400 MHz, CDCl₃) 4.29-4.36 (1H, m, H-3), 4.21 (1H, t, *J* = 7.9 Hz, H-4), 3.65 (1H, dd, *J* = 6.4, 7.9 Hz), 1.49 (9H, s, CO₂C(C<u>H₃)₃</u>), 1.48 (9H, s, CO₂C(C<u>H₃)₃</u>), 1.45 (3H, d, *J* = 6.4 Hz, CHC<u>H₂</u>); ¹³C NMR (100 MHz, CDCl₃) 160.1 (1C, CO₂C(CH₃)₃), 160.0 (1C, CO₂C(CH₃)₃), 81.8 (1C, CO₂C(CH₃)₃), 81.7 (1C, CO₂C(CH₃)₃), 57.4 (1C, C-3), 55.6 (1C, C-4), 28.13 (3C, CO₂C(CH₃)₃), 28.12 (3C, CO₂C(C<u>C</u>H₃)₃), 20.7 (1C, CHC<u>C</u>H₃); MS (ES⁺) *m*/*z* = 295 [M+Na]⁺, HRMS (ES⁺) *m*/*z* calculated for C₁₃H₂₄N₂O₄Na [M+Na]⁺: 295.1652; found: 295.1652. Enantiopurity by HPLC analysis on a Chiralcel AD column (1.0 mL min⁻¹, 1% IPA in hexanes): *t_R*9.20 (*minor*) and 9.93 (*major*) min.}

Reductive Cleavage of (S)-5a to (S)-19. Freshly cut pellets of lithium (66 mg, 9.40 mmol) were placed in a flask containing 4,4'-di-tert-butylbiphenyl (500 mg, 1.88 mmol). The tube was evacuated and filled with argon 3 times. THF (5 mL) was added and stirring continued for 15 minutes, whereupon the solution turned dark green. The vessel was cooled to -78 °C under an argon atmosphere and the resulting solution of LiDBB used immediately. To (S)-5a (87 mg, 0.40 mmol, 89%ee) in THF (3 mL) at -78 °C was added the LiDBB solution until the dark green colour persisted. The reaction mixture was stirred for a further 30 minutes, and then quenched by the addition of saturated aqueous NH₄Cl (1 mL). After warming to room temperature, diethyl ether (2 mL) was added. The layers were separated and the aqueous layer extracted with Et₂O (3 \times 10 mL). The combined organic layers were dried over MgSO₄, filtered, and concentrated in vacuo. Purification on silica gel (20% EtOAc in hexane) afforded (S)-19 (56 mg, 64%, 84%ee) as a white crystalline solid. M.p. 132-133 °C; $[\alpha]_{D}^{30} = -11.1$ (*c* 1.75, EtOAc). IR (neat) 3308 (N-H), 2980 (CH₃), 1681 (C=O) cm⁻¹; ¹H NMR (400 MHz, CDCl₃), 5.28 (1H, br s, NH), 5.02-5.11 (1H, br m, NH), 4.02-4.10 (4H, m, CO₂CH₂CH₃), 3.77 (1H, br m, H-2), 3.15-3.29 (2H, m, H-2), 1.19 (6H, br t, J = 7.1 Hz, CO₂CH₂CH₃), 1.12 (3H, d, J = 6.7 Hz, H-3); ¹³C NMR (100 MHz, CDCl₃) 157.4 (1C, <u>CO₂CH₂CH₃</u>), 156.6 (1C, <u>CO₂CH₂CH₃</u>), 60.9 (1C, CO₂<u>C</u>H₂CH₃), 60.7 (1C, CO₂CH₂CH₃), 47.6 (1C, C-2), 46.4 (1C, C-1), 18.4 (1C, C-3), 14.6 (2C, CO₂CH₂CH₃); MS (ES⁺) $m/z = 241 \text{ [M+Na]}^+$, HRMS (ES⁺) m/z calculated for C₉H₁₈N₂O₄Na [M+Na]⁺: 241.1159; found: 241.1157.

EtO₂CHN NHCO₂Et Authentic Sample of (\pm) -19 from 1,2-diaminopropane. To a stirred solution of commercial (\pm) -1,2-diaminopropane (Aldrich, 1.0 g, 13.5

mmol) and potassium carbonate (2.56 g, 27.0 mmol), in THF (20 mL) was added ethyl chloroformate (2.57 mL, 27.0 mmol) and the reaction was stirred for 4 h at 25 °C. The mixture was poured into water (50 ml) and extracted with diethyl ether (3 x 50 mL). The combined organic layers were dried over MgSO₄, filtered and concentrated *in vacuo*. Recrystallization from hexane afforded (\pm)-**19** (1.85 g, 63%) as a white crystalline solid. Data as previously described.

Authentic Sample of (R)-19 from (R)-1,2-diaminopropane. To a stirred solution of commercial (R)-1,2-diaminopropane (Aldrich, 0.5 g, 3.40 mmol) and potassium carbonate (1.36 g, 14.28 mmol) in THF (10 mL) and water (10 mL) was added ethyl chloroformate (0.68 mL, 7.14 mmol) and the reaction was stirred for 4 h at 25 °C. The mixture was poured into water (50 ml) and extracted with diethyl ether (3 x 50 mL). The combined organic layers were dried over MgSO₄, filtered and concentrated *in vacuo* to afford (*R*)-**19** (734 mg, 99%) as a white crystalline solid. $[\alpha]_{D}^{30} = +12.5$ (*c* 1.75, EtOAc). Data as previously described.



Figure 1. ¹H NMR Spectra (400 MHz, d_6 -benzene) of (±)-**19** in the presence (*S*)-(+)-1-(9-anthryl)-2,2,2-trifluoroethanol.

Figure 2. ¹H NMR (400 MHz, d_6 -benzene) of (*R*)-**19** and (±)-**19** in the presence of (*S*)-(+)-1-(9-anthryl)-2,2,2-trifluoroethanol.



Figure 3. ¹H NMR (400 MHz, d_6 -benzene) of enantioenriched (*S*)-**19** (from LiDBB reduction) in the presence (*S*)-(+)-1-(9-anthryl)-2,2,2-trifluoroethanol. Opposite signals enhanced relative to authentic sample derived from (*R*)-1,2-diaminopropane. From integrals, (*S*)-**19** was determined to be 84%ee.



Figure 4. ¹H NMR (400 MHz, CDCl₃) of **5**a.



Figure 5. 13 C NMR (100 MHz CDCl₃) of 5a.



Figure 6. ¹H NMR (400 MHz, $CDCl_3$) of **5b**.



Figure 7. ¹³C NMR (100 MHz, CDCl₃) of **5b**.



Figure 8. ¹H NMR (400 MHz, CDCl₃) of 5c.



Figure 9. 13 C NMR (100 MHz, CDCl₃) of 5c.



Figure 10. ¹H NMR (400 MHz, CDCl₃) of (*S*)-**19**.



Figure 11. ¹³C NMR (100 MHz, CDCl₃) of (*S*)-**19**.

